Method of treating secondary lactase deficiency. RU patent 2477633.

IPC classes for russian patent Method of treating secondary lactase deficiency. RU patent 2477633. (RU 2477633):

A61P1/14 - Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

A61K35/66 - Materials from micro-organisms

A61K31/472 -

Another patents in same IPC classes:

Use of ghrelin splicing version for treating cachexia and/or anorexia, and/or anorexia-cachexia, and/or eating disorder, and/or lipodystrophy, and/or muscle atrophy, and/or appetite stimulation / 2470940
Invention provides using a prepared compound of a ghrelin splicing version for preparing an effective drug preparation activating body weight and food intake gain and/or stimulating growth hormone release, as well as for treating or preventing cachexia, lipodystrophy and muscle atrophy.

Probiotic in pre- and/or postoperative period / 2470652
What is presented is the use of the strain Lactobacillus johnsonii in preparing a probiotic composition for prevention of postoperative abdominal and pelvic infections caused by pelvic liquid accumulation, anastomosis leakage, or caused by bacterial translocation.

Application of indigestible saccharides for better adaptation of newborns / 2462252
There are offered: application of a water-soluble indigestible saccharide for preparing a composition wherein the composition is introduced in a pregnant woman for improving the developing intestinal microflora of an expected newborn; reinforcing the immune system and/or preventing the diseases associated with the immune system of the expected newborn; or reinforcing the immune system of the foetus (versions). What is also presented is the application of the water-soluble indigestible saccharide wherein the saccharide is a galactose-containing saccharide containing at least 50% of galactose units of the total amount of monosaccharide units found in the saccharide for preparing the composition for reinforcing the immune system of the pregnant woman; improving the vaginal flora of the pregnant woman wherein the composition is introduced in the pregnant woman.

Method of treating dyspepsia in calves / 2461387
Invention relates to veterinary science. A method includes the administration of a medicinal agent. The medicinal agent is presented by 0.25% alcohol solution of Chlorophyllipt 3 ml in normal saline 57 ml which is introduced intravenously twice a day for 2-3 days in dose of 60 ml per a calve if observing simple dyspepsia and four times if observing toxic dyspepsia. It is combined with the oral introduction of 1% alcohol solution of Chlorophyllipt 10 ml at 900 ml in normal saline prescribed twice a day in dose 1000 ml in both forms of dyspepsia.

Bifidobacterium longum strain used for preparing bifidus products / 2460777
Strain Bifidobacterium longum B-NH is recovered from a healthy infant, actively propagates in a nutrient medium with accumulation of an production biomass in a short 12-18-hour period of cultivation time of the high bifidus bacteria concentration, is able to sour milk. The Bifidobacterium longum B-NH strain exhibits acid-forming activity, pathogen and opportunistic pathogen antagonist activity. It makes it possible to use the strain Bifidobacterium longum B-NH as an ingredient of bifidus products - bacterial preparations, biologically active food additives, fermented and non-fermented foodstuff, toiletry and care preparations enabling normalised human body microbiocenosis, including gastrointestinal and urogenital tracts, skin and mucous membranes, and extends the range of products for correction of human microflora. The strain Bifidobacterium longum B-NH is deposited in Russian National Collection of Industrial Microorganisms, No. VKPM Ac-1876.

Method of complex treatment of dysbacteriosis at resort stage / 2460508
Invention relates to medicine, namely to balneology, physiotherapy. First, individual sensitivity of patient to radon procedures is estimated. For this purpose, arterial pressure and heart rate are measured on empty stomach. After that, patient takes bath with mineral water from thermal radon springs with natural water temperature about 38°C (radon water). Patient rests for 30 minutes. After that, patient's arterial pressure and heart rate are re-measured. If heart rate does not change or changes by ±10 beats/min, and systolic and/or diastolic arterial pressure changes by ±10 mm Hg, I type of response is determined in patient. If heart rate changes by ±20 beats/min, and systolic and/or diastolic arterial pressure changes by ±15 mm Hg, II type of response is determined in patient. If heart rate changes by ±30 beats/min, and systolic and/or diastolic arterial pressure changes by ±20 mm Hg, III type of response is determined. In case of I type of response bath is taken according to the scheme: first procedure - 5 minutes, second - 8 minutes, third - 10 minutes, after that all procedures last 15 minutes. In case of II type of response bath is taken according to the scheme: first procedure - 5 minutes, second - 8 minutes, third - 10 minutes, after that all procedures last 12 minutes. In case of III type of response bath is taken according to the scheme: first procedure - 3 minutes, second - 5 minutes, third - 8 minutes, after that all procedures last 10 minutes. Course includes 10-15 baths. Bath with radon water is taken two days running, which are followed by one-day break. Treatment is performed at the background of diet No 4 b. In the first part of the day, two hours after breakfast, patient drinks 200 ml of radon water in swallows at a measured pace. On one of the days with baths, going one after another, microclysters with pantohematogen are performed. Detensor-therapy is carried out. In the second part of the day, two hours after dinner, patient drinks 200 ml of radon water in swallows at a measured pace. After that, patient takes bath with radon water. Then, procedure in accordance with programme of resonance-acoustic fluctuations (PRAF) is performed. On the days without baths in the first part of the day intestinal lavage is performed and in the second part of the day - thalassotherapy of face and body.

Oral composition containing nonpathogenic microorganisms showing ability to normalise intestinal microflora (versions) / 2453320
Group of inventions refers to pharmaceutical industry and medicine and is applicable for producing and using medical immunobiological preparations containing nonpathogenic microorganisms. The compositions (versions) represent a powder containing substances containing nonpathogenic microorganisms dried up in a culture medium specified in a number: Bifidobacterium bacteria and/or Lactobacillus bacteria, and/or species-specific virulent bacteriophages, and/or species-specific bacteriophages with induced virulence or their combinations with the composition containing target additives able to form a stable foam structure, is characterised by porous structure and fragility, has a relative disintegration shrinkage at least 10 %, equivalent pore diameter 10-110 mcm at particle size no more than 100 mcm and a resting angle less than 50° in the following proportions in 1.0 g of the composition: Bifidobacterium bacteria 106-1010 CFU and/or Lactobacillus bacteria 106-1010 CFU, and/or species-specific virulent bacteriophages of Appelman's lytic activity at least 10-4 with respect to test strains and bacterial isolates recovered from a human body, and/or species-specific bacteriophages of induced virulence of Appelman's lytic activity at least 10-4 with respect to test strains and bacterial isolates recovered from a human body, target additives - the rest.

Pharmaceutical composition 'mycenorm' with antacidic action / 2442591
The invention relates to creation of pharmaceutical composition in the form of suspension with antacidic action. The said pharmaceutical composition contains calcium carbonate, polysaccharide sodium salt and excipients, where calcium carbonate is presented by “Micellate of calcium carbonate and magnesium”, polysaccharide sodium salt is sodium hyalurate. The composition additionally contains dimephosphon (dimethyloxobuthylphosphonilmethylate) and water. The excipients are alcohol, Nipagin and fructose. Offered pharmaceutical composition has specific pharmacological expressed effect, it showed atacidic action on the model of experimental gastritis. The composition has no expressed toxic effect with various doses and routes of experimental animals.

Controlled release pharmaceutical compositions unstable in medicinal acid medium / 2440101
Invention refers to pharmaceuticals and concerns a controlled release pharmaceutical composition containing an oral dosage form of pancreatine, and an enterosoluble coating which contains a) a film-forming agent; b) a plasticiser representing mixed cetyl alcohol and triethyl citrate, and c) optionally at least one adhesion-blocking agent. The invention also concerns a method for preparing said composition and applying it for producing a pharmaceutical for digestive disorders, pancreatic exocrine insufficiency, pancreatitis, mucoviscidosis, insulin-dependent and/or insulin-independent diabetes.

Gastrointestinal herbal tea / 2437673
Invention relates to pharmaceutical industry and can be applied for increase of therapeutic-preventive properties of medicinal vegetable mixture for treatment of gastrointestinal tract diseases. Gastrointestinal herbal tea contains leaves of mint, rhizomes of sweet flag, flowers of chamomile, root of licorice and fennel fruits in defined component ratio.

Method of treating non-alcoholic fatty liver disease / 2473342
Invention relates to medicine, namely to gastroenterology and can be used for treatment of non-alcoholic fatty liver disease. For this purpose administered are metronidasol 250 mg 4 times per day, alpha-normix 200 mg 2 tablets x 2 times per day during 7-10 days.After that, treatment is performed with further administration of bifiform in dose 2 capsules in the morning, probifor in dose 25-30 doses 3 times per day, linex in dose 2 capsules 3 times per day, hylak forte 40-60 drops 3 times per day, sporobacterin 2-4 ml. Duration of intake constitutes 3-4 weeks, also administered is dufalak in dose 5-10 ml per day. Drug therapy of lipid metabolism disorders is performed in dependence of biochemical parameters: in case if ultrasonic signs of steatosis are present and level of transaminases is normal, statins in combination with ezetimibe are administered. If transaminases increase to 3 normal values, essential phospholipids are applied during 3 months. If transaminases increase higher than 3 normal values, ursodeoxycholic acid in dose 15-20 mg/kg is applied; if ultrasonic signs of non-alcoholic steato hepatitis are present and transaminases increase to 3 normal values, statins are administered in dose 20 mg and ursodeoxycholic acid in dose 15-20 mg/kg for 3-6 months. If transaminases increase higher than 3 normal values, treatment is performed with statins in dose 20-40 mg/day and ursodeoxycholic acid in dose 15-20 mg/kg, ezetimibe in dose 10 mg 1 time per day.

Therapeutic antimalaria drug based on antimalaria agent and probiotic / 2472505
Invention refers to medicine and biotechnology and represents a therapeutic antimalaria drug containing an antimalaria agent and excipients differing by the fact that it additionally contains a biomass of the Bacillus subtilis probiotic strains in the amount of CFU not less than 1×108 cell/tablet (dose) with the ingredients in the preparation taken in certain proportion, wt %.

Bacterial extract for gastrointestinal or urinary disorders and method for preparing it / 2457848
Invention refers to medicine and pharmacy and represents an immunostimulating extract of one or more bacterial strains Escherichia coli wherein the process of preparing the extract involves lysing one or more bacterial strains at pH more than 12 and processing the extract to separate nucleic acids, and wherein the extract: causes no risk of a prion disease when introduced into the patient, contains less than 100 mcg/ml of nucleic acid, contains chemically modified saccharides, including chemically modified lipopolysaccharide, and contains at least one amino acid which is specified in aspartic acid, glutamic acid, serine, histidine, alanine, arginine, tyrosine, methionine, phenylalanine and lysine; and it is racemised at least by 10%.

Bacterial extract for respiratory disorders and method for preparing it / 2456007
Invention refers to medicine and pharmacy and represents an immunostimulating extract of one or more bacterial species specified in Moraxella catarrhalis, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes and Streptococcus sanguinis, wherein while preparing said extract one or more bacterial strains are lysed at pH more than 12, and the extract is processed in order to remove nucleic acids; and wherein the extract dies not cause the onset of a prion disease if introduced into a patient wherein the extract contains less than 100 mcg/ml of nucleic acid, wherein the extract contains chemically modified saccharide, including chemically modified lipopolysaccharide, and wherein at least one amino acid which is specified in aspartic acid, glutamic acid, serine, histidine, alanine, arginine, tyrosine, methionine, phenylalanine and lysine, is racemised at least by 10%.

Method of treating patients suffering pulmonary tuberculosis / 2456006
Invention refers to medicine, namely to phthisiology, and may be used for treating patients with pulmonary tuberculosis. That is ensured by conducting the tuberculosis therapy in compliance with the standard schedules and additionally prescribing the probiotic biologically active additive SimBiovital 9.0 g in a single dose every second day with food for two months, and also the Hepel 1 tablet once a day sublingually daily for four months.

Method for prevention of cattle technological stresses / 2446813
Invention relates to veterinary science. A method involves in the fact that the biological preparation lactoenterol 50 g per a head is introduced in animals before stress exposure.

Using actinomycetes lysate for preparing dermatics for treating acne and method of treating acne / 2445968
Invention refers to dermatology and represents using lysate of strains Actinomyces R/3.88, L/1.89 or their mixtures for preparing dermatics for treating acne, as well as a method for treating acne characterised by the fact that actinomycetes lysate according to cl.1 is applied on skin of a patient in need thereof.

Mean chain length dicarboxylic acid, their derivatives and metabolic disorders / 2445955
Invention refers to medicine and pharmacology and represents using a composition containing sebacic acid and/or its derivatives selected from salts and esters for making a product for oral and enteral introduction which is applicable for: (i) treating or preventing peripheral insulin resistance, impaired glucose tolerance, diabetes, hyperglycemia and related disorders, such as nephropathy, retinopathy, cardiac and cardiovascular diseases (ii) increased glucose clearance and/or insulin responsitivity; (iii) hepatic glucose formation inhibition or (iv) reduced endogenous glucose production.

Method of obtaining biologically active substance from embrionic-egg mass for preparation of anti-burn plate and anti-fire plate on its base / 2433171
Non-infected fresh hen eggs are selected with their further incubating for 9 days. On 5, 6, 7 days hen egg is radiated for 30 s at frequency of modulation 9 Hz and radiation voltage 9 mW with further cooling of eggs for 6-7 days at temperature 2-4°C and homogenisation of eggs. Obtained homogenate is subjected to processing by ultrasound in ultrasonic dispersant. To homogenate, processed with ultrasound, added is mixture, containing 0.1% solution of sodium benzoate and 0.1% of solution of potassium sorbate in equal parts, in weight ratio 1:1 respectively with further ultramicrofiltration through filters with 0.2 mcm diameter, obtaining biologically active substance for embryonic-egg mass. Homogeneous mass is prepared in the following way. Medical gelatin is covered with decoction, containing calendula decoction and chamomile decoction in weight ratio 1:1, keep at temperature 20-25°C for 55-60 minutes with further placement of decoction with gelatin on water bath at temperature 65-70°C until complete dissolusion of gelatin is obtained. Into obtained decoction with gelatin added are amikacin, furacilline, anesthesin, amaranth oil, glycerol and brilliant green with further mixing in homogeniser for 4-5 min obtaining homogeneous mass. To obtained homogeneous mass biologically active substance from embryonic-egg mass is added in specified ratio and mixed in homogeniser for 5-7 min. Obtained mass is poured into special vessels and are placed in thermostat for 3.5-4 hours at temperature 37-39°C with further cooling for 1-2 days until plates solidify in form of plates.

Method of treating consequences of infantile cerebral paralysis / 2477097
Invention relates to medicine, namely to neurology, restorative medicine, and can be applied in treatment of consequences of infantile cerebral paralysis. For this purpose reflex low temperature impact on nerve plexuses of peripheral artery is performed. Said impact is performed first in lower third of forearm, and after three months in first interdigital space of foot. Cryoapplicator with diameter 2 mm is installed on exposed peripheral artery and double cryogenic impact with duration 10 seconds is performed at temperature minus 186°C. In the period between low temperature impacts complex drug therapy is carried out: in the first two weeks administered are detralex in dose 1 capsule 2 times per day, nicospan in dose 1 tablet 3 times; in the second two weeks grandaxin in dose 0.05 in the morning; spasgan in dose 1 tablet in the afternoon; atarax in dose 1/2 tablet before going to bed.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly gastroenterology, and may be applied in treating secondary lactase deficiency. For this purpose, with underlying diet and drug-induced therapy, bifiform 1 tablet 2-3 times a day and No-spa 1-2 tablets 3 times a day are additionally administered. The therapeutic course makes 14 days.

EFFECT: method enables higher clinical effectiveness in secondary lactase deficiency.

3 ex

The invention relates to medicine, can be applied in the treatment of secondary lactase deficiency.

Known method of treatment of the disease with the help of enzymes in the background diet (1 - .., ..., .. and other Efficiency of application of and diet at disease of newborns. Issues of children's nutrition, 2003, Vol.1, №4, 21-25). The method adopted as analogue.

Known method of treatment of lactase deficiency, which consists in the fact that the treatment was carried appointment of the drug Lactase Enzyme in the dose of 7 mg (700 units). (1 capsule child forms) per 100 ml of expressed breast milk (or 350 units of 50 ml); drug interfered in milk in each feeding (2 - .., N.V. Stepanova drug Use Lactase Baby for the treatment of the disease in newborns. Found: Google http://www.lactase.ru/publications/using-lactase-baby.html). This method is taken as a prototype.

However, the effectiveness of the prototype method is limited.

The present invention is to increase the effectiveness of treatment of secondary lactase deficiency.

The technical result is achieved by the fact that in the scheme of treatment of patients with secondary lactase deficiency added as a daily dose Bifiform 1 tab. 2-3 times and no-Spa - table 1-2. 3 times a course of treatment for 14 days.

The method is implemented as follows.

Patients with a diagnosis of secondary lactase deficiency proceed with complaints about bloating, rumbling, periodic pains in the abdomen, moderate intensity, without irradiation, not connected with meals; constipation up to 2-4 days, which are regulated diet. Chair decorated, not plentiful without admixture of mucus and blood. Appetite saved. Weight stable.

From an anamnesis it is known that patients with long-suffering and epigastric pain after eating, noted the spring/autumn exacerbation.

Objectively: a satisfactory condition, HELL 110-130/70-90 mm RT. senior HR 60-80 min-BH 16-18 in minutes Muffled heart sounds, rhythm right. In light of wheezing no, vesicular breath. Tongue wet, white furred. Abdomen soft, moderately painful in region. The results of the survey:

ECG: position of the EOS. Rhythm sinus correct. Mild diffuse changes of the myocardium.

EGD: Esophagus pass. Esophageal mucosa pink, cardia interlocked. In the stomach cavity moderate amount of mucous content; slimy pink, moderately sophisticated. The folds of medium size, elastic. Peristalsis is traced in all departments. The angle of the stomach is not modified. The porter closed, we pass. Onion duodenum medium in size, is not deformed. The mucosa of the duodenal and mucous Department pink. The folds of medium size, elastic. Skinny gut b/O. Urease test is negative. test is positive.

Biopsy: the fragments of the mucous membrane duodenal ulcer of the proximal: in the submucosal layer cancer, intestinal villi, normal height, the crypt shallow. The number of MEL within the norm. The private plate small lymph infiltration. The mucosa of the duodenum of normal structure.

According to the respiratory hydrogen test revealed bacterial overgrowth.

Ultrasound of the abdomen, the Liver acts under the edge of a costal arch. Edge rounded, smooth, outline a clear, capsule is not thickened. The size of the liver are not enlarged. Structure is homogeneous. Total echogenicity parenchyma average. Diameter of the portal vein and the inferior Vena cava is normal clearance homogeneous. Vascular figure saved. The gallbladder is of irregular shape, dimensions are not enlarged. The bladder wall are thin, smooth, homogeneous structure. In the cavity of a bubble is defined homogeneous content concrements no. ducts are not extended, the wall smooth, segmental and equity significantly expanded, the lumen of homogeneous. The common bile duct is not extended, the wall smooth clearance homogeneous. The pancreas is rendered satisfactory, contour fuzzy, surface smooth. The structure is homogeneous, echo is average. Pancreatic duct is not extended, the walls are sealed. Lesions were revealed. Spleen is rendered adequately, outline a clear, smooth surface. Free fluid in the abdominal cavity no. Conclusion: the deformation of the gallbladder.

Sigmoidoscopy: on external inspection finger study - internal hemorrhoids are not pronounced. Sphincter tone saved. Tube introduced on 25 see Slimy pink, smooth, shining. Vascular figure clear. Ulcers, polyps, tumors were revealed. Conclusion: organic pathology was revealed.

Consultation of endocrinologist: thyroid goiter 1 tbsp. .

EMA intestine: hypermotor dyskinesia of the stomach, - rising division of the colon.

Breath hydrogen test with lactulose (duphalac): bacterial overgrowth periodically detected.

Treated secondary lactase deficiency, including diet. As drugs used daily as a daily dose Mezym Forte 1 table. X 2-3 times, Bifiform 1 tab. 2-3 times and no-Spa - table 1-2. 3 times a course of treatment for 14 days.

After the treatment, bloating, rumbling, pain in area disappeared. Stool was normalized.

During the follow-up monitoring for 1 year spring-autumn exacerbation not observed.

Way to implement further illustrated by the following examples.

Example 1

Sick C., 1983 year of birth, came with complaints of periodic pains in area of moderate intensity, without irradiation, not associated with eating, bloating, rumbling in the stomach; constipation up to 4 days regulates diet (prunes, dried apricots), designed, not plentiful, day, without any admixture of mucus and blood. Appetite saved. Weight stable.

From an anamnesis: considers herself a patient in 10 years, when for the first time an aching pain in epigastria after a meal, was observed in a gastroenterologist with a diagnosis of chronic gastroduodenitis, a marked exacerbation spring/autumn. On a diet, took antacids with a positive effect. 3 years ago, have constipation up to 4 days. Not examined, is not treated. Recently, the patient appeared periodic pains in region. Took with a weak positive effect.

Objectively: a satisfactory condition, HELL 110/70 mm RT. senior HR 78 minutes BH 18 minutes muffled heart sounds, rhythm right. In light of wheezing no, vesicular breath. Tongue wet, white furred. Abdomen soft, moderately painful in region. Chair was gone. The results of the survey:

ECG: position of the EOS. Rhythm sinus correct. Mild diffuse changes of the myocardium.

EGD: Esophagus pass. Esophageal mucosa pink, cardia interlocked. Stomach: stomach cavity moderate amount of mucous content. The mucosa of the stomach pink, moderately sophisticated. The folds of medium size, elastic. Peristalsis is traced in all departments. The angle of the stomach is not modified. The porter closed, we pass. Onion duodenum medium in size, is not deformed. The mucosa of the duodenal and mucous Department pink. The folds of medium size, elastic. Urease test is negative. Conclusion: chronic gastritis. test weakly positive.

Biopsy: the fragments of the mucous membrane duodenal ulcer of the proximal - in the submucosal layer cancer. Intestinal villi, normal height. Crypt shallow. The number of MEL within the norm. The private plate small lymph infiltration. Conclusion: the mucosa of the duodenum of normal structure.

Breath hydrogen test - diagnosed bacterial overgrowth (91 ppm).

Ultrasound examination of abdominal cavity: registered omission of bodies of a belly cavity. Liver: visualizes adequately; acts under the edge of a costal arch. Edge rounded, smooth, outline a clear, capsule is not thickened. The size of the liver are not enlarged (HDP the right lobe of 125 mm, the thickness of the left lobe of 58 mm). Structure is homogeneous. Total echogenicity parenchyma average. Diameter of the portal vein 9 mm, diameter NIP 17 mm; clearance homogeneous. Vascular figure saved. Gall bladder: irregular shape. Dimensions are not enlarged: 53 x 17 x 27 mm, volume 17 ml of the bladder Wall are thin, smooth, homogeneous structure. In the cavity of a bubble is defined homogeneous content concrements no. In the lower third of the body closer to the neck - education sizes 6,2 x 2,9 mm, homogeneous structure, when scanning in the DRC. ducts are not extended, the wall smooth, segmental and equity significantly expanded, the lumen of homogeneous. The common bile duct is not extended (3.5 mm), wall smooth clearance homogeneous. The pancreas is rendered satisfactory, contour fuzzy, surface smooth. Dimensions: 19 x 15 x 17 mm Structure is homogeneous, echo is average. Pancreatic duct is not extended, the walls are sealed. Lesions were revealed. Spleen is rendered adequately, outline a clear, smooth surface. Size: 94 x 39 mm Echo parenchyma increased, the structure is homogeneous. Vienna in diameter of 6 mm clearance homogeneous. Free fluid in the abdominal cavity no. Conclusion: ultrasound signs , deformation of the gall bladder, gall bladder polyp.

When rectoromanoscopy internal hemorrhoids are not pronounced. Sphincter tone saved. Tube introduced on 25 cm - next bend, pain. Slimy pink, smooth, shining. Vascular figure clear. Ulcers, polyps, tumors were revealed. Conclusion: organic pathology was revealed. Consultation with a gynaecologist: cancel oral contraceptives, consultation of endocrinologist. Consultation of endocrinologist: thyroid Goiter 1 tbsp. .

EMA intestine: hypermotor dyskinesia of the stomach, - rising division of the colon.

Consultation with physiotherapist: circular douche №5, AVERS-lamp №5. Colonoscopy: the device held in the dome of the cecum. Б flap form, , focuses dome. In the lumen of the moderate quantity of liquid. Loops of the colon is omitted, . Sigmoid forms a loop. The mucosa of the colon at the inspected sites pink, smooth, shining. Vascular figure clear, correct. The folds of mucous average, elastic. The lumen is not deformed. The tone of the bowel is reduced. Ulcers, polyps, tumors were revealed. Conclusion: the examined areas of organic pathology from the side of the colon is not revealed.

The final diagnosis: Chronic gastritis in the phase of exacerbation. Syndrome excessive bacterial growth. Lactase deficiency moderate severity. . A cholesterosis of a gall bladder, form. Thyroid goiter 1 tbsp. .

Laboratory data:

The General analysis of a blood:

Indicator

Norm

Indicator

Norm

Hemoglobin

13,2 14

P/nuclear

1 1-6

Erythrocytes

4,49 3,9-4,7

The segment.

58 47-72

Hematocrit

39,8 39-50

Eosinophiles

2 0-5

Leukocytes

7,3 4-9

Lymphocytes

33 19-37

Platelets

370 150-400

Monocytes

6 3-11

Erythrocyte sedimentation rate

8 3-15

Biochemical blood test:

Indicator

24.11.10 13.12.10 Norm

About. protein

73,4 66-87

Total bilirubin

14,8 3,4-21

Bilirubin etc.

2,7

Cholesterol

7,27 6,91 1,4-5,2

Triglycerides

1,7 0-1,7 LDL-C 4,1 2,1-3,3 Glucose 4,46 4,1-5,9 Urea 4,58

of 1.7 to 8.3

Iron 32,1

10,7-32,2

MHO 0,98 0,9-1,2

Prothrombin

100 70-130

Indicator

Result Date HIV

negativity.

29.11.10 RW

negativity.

29.11.10

Blood analysis - HBs Ag and anti-HCV - not detected. Clinical analysis of urine - transparent, protein neg., beats./weight 1019, leukocytes, erythrocytes, ketones, glucose - no. Feces analysis reaction occult blood - negativity.

Treatment. Б diet. Add as a daily dose Mezym Forte 1 table. x 2 times, Bifiform 1 tab. 2 times and no-Spa - 1 table. 3 times a course of treatment for 14 days.,

The patient was physiotherapeutic treatment: Avermes-lamp №5, circulatory shower №5. Against the background of therapy of the patient marks an improvement in their condition reduced pain in the abdomen, normalization of stool to 1 time per day, issued, without pathological admixtures. Works, disability has not. The prognosis is favorable. During the follow-up monitoring for 1 year spring-autumn exacerbation not observed.

Example 2

Patient Zh., 1985 year of birth, entered complaining of periodic pains in area of moderate intensity, aggravated before the act of defecation, after defecation, bloating, rumbling in the abdomen, bloating; occasionally belching air. Chair , up to 3-4 times a day, in the daytime not plentiful, with no admixture of mucus and blood. Appetite is reduced, lost in the last 4 months. 5 kg

History of present illness: considers himself to be ill within 1 year, when due to stress appeared rapid chair up to 3 times a day, periodic pains in the abdomen, mainly in region. Took enzymes with a positive effect. Not surveyed. Having dragging pain in region, especially in the right half of the abdomen, nausea, and under the SMP was hospitalized.

When ultrasound of the abdomen ultrasound signs of digestive pathology were revealed. During the colonoscopy of organic disease of the colon is not revealed. In the General analysis of blood leukocytes 9 (ULN), in the analysis of the blood - without pathological changes. Held therapy with a positive effect, encouraged the reception of CREON, observation gastroenterologist m/place of residence. However, the patient remained abdominal pain, chair was 3-4 times a day, without admixture of mucus and blood.

Was admitted for examination and treatment. Objectively when you receive: a satisfactory condition, HELL 120/70 mm RT. senior HR 70 min. BH 18 minutes muffled heart sounds, rhythm right. In light of wheezing no, vesicular breath. Tongue wet, white furred. Abdomen soft, moderately painful to palpation in and left iliac region. The chair was 1 per day, without admixture of mucus and blood.

The results of the survey:

ECG: position of the EOS. HR 67. Rhythm sinus correct.

EGD: Esophagus pass. Esophageal mucosa pink, cardia interlocked. Stomach: stomach cavity moderate amount of mucous content and bile. The mucosa of the stomach pink, hyperemic on the tops of the folds. The folds of medium size, elastic. Peristalsis is traced in all departments. The angle of the stomach is not modified. Gatekeeper yawning, we pass. Onion duodenum medium in size, is not deformed. The mucosa of the duodenal of the Department of pink. The folds of medium size, elastic. Skinny gut b/O. Urease test is negative. test is positive. Conclusion: superficial gastritis, duodeno-gastric reflux.

Biopsy: chronic weak duodenitis. Signs of celiac disease in the investigated material not.

Ultrasound of the abdomen, the Liver: visualizes adequately; not acting under the edge of a costal arch. Edge rounded, smooth, outline a clear, capsule is not thickened. The size of the liver are not enlarged (HDP the right lobe of 140 mm, thickness of the left lobe of 76 mm). Structure is homogeneous. Total echogenicity parenchyma average. Diameter of the portal vein 10 mm, diameter NIP 19 mm; clearance homogeneous. Vascular figure saved. Gall bladder: the correct form. Dimensions are not increased: 60 x 23 x 35 mm, volume 30 ml thin Wall of the bladder. In the cavity of a bubble is defined homogeneous content concrements no. , segmental and equity are not extended, the wall smooth clearance homogeneous. The common bile duct is not extended (5.0 mm), wall smooth clearance homogeneous. The pancreas is rendered satisfactory, surface smooth. Dimensions: 24 x 16 x 22 mm Structure of homogeneous fine-grained. Total echo is average. Pancreatic duct is not expanded. Lesions were revealed. Spleen is rendered adequately, outline a clear, smooth surface. Size: 94 x 40 mm Echo is parenchyma average, the structure is homogeneous. Vienna in diameter of 6 mm clearance homogeneous. Free fluid in the abdominal cavity no. Right kidney: in registered 1 tbsp. Dimensions 101 x 49 mm, diffuse cortical layer homogenous and uniform thickness (14 mm). Expansion not registered. Concrements no. Respiratory mobility saved. The left kidney: location typical. Dimensions 100 x 52 mm, cortical layer of a homogeneous structure, thickness up to 15 mm not extended, . Concrements no. Respiratory mobility saved. Conclusion: right 1 tbsp.

Colonoscopy: the apparatus is carried out in part of the terminal ileum 20 see the Mucosa of the small intestine pink, velvety, peristalsis its active. Are defined by the single hypertrophied lymphoid follicles with the size up to 0,2 sm in diameter. Б flap form, , focuses dome. In the lumen of the moderate quantity of liquid. Sigmoid forms a loop. The mucosa of the colon at the inspected sites pink, smooth, shining. Vascular figure clear, correct. The folds of mucous average, elastic. The lumen is not deformed. The tone of the ulcer saved. Ulcers, polyps, tumors were revealed. Conclusion: organic pathology from the side of the colon is not revealed.

Laboratory data:

The General analysis of a blood:

Indicator

Norm

Indicator

Norm

Hemoglobin

14,8 17,3

P/nuclear

1 1-6

Erythrocytes

4,97 3,9-5,7

The segment.

61 47-72

Hematocrit

43 39-50

Eosinophiles

2 0-5

Leukocytes

5,8 4-9

Lymphocytes

30 19-37

Platelets

282 150-400

Monocytes

6 3-11

Erythrocyte sedimentation rate

4 3-15

Biochemical blood test:

Indicator

Norm

About. protein

74,8 66-87

Total bilirubin

18,6 3,4-21

Cholesterol

3,79 1,4-5,2 Glucose 4,78 4,1-5,9 Urea to 5.21

of 1.7 to 8.3

MHO 1,03 0,9-1,2

prothrombin

96,4 70-130

Indicator

Result Date HIV

negativity.

18.11.10 RW

negativity.

18.11.10

Blood analysis - HBs Ag and anti-HCV is not found.

Clinical analysis of urine - transparent, protein neg., beats./weight 1014, leukocytes, erythrocytes, ketones, glucose - no. Feces analysis reaction occult blood test negative. Diastasis urine is normal, 311,1 U/L. Treatment: Б diet. Additionally used as a daily dose Mezym Forte 1 table. x 3 times, Bifiform 1 tab. 3 times and no-Spa - 2 table. 3 times a course of treatment for 14 days.

Against the background of therapy of patient notes improvement in their condition: abdominal pain cropped, stool was normalized to 1 time per day, decorated , without pathological admixtures. The prognosis is favorable.

Example 3

Patient K., 1960 year of birth, complaints at entering periodic pains in region, not associated with eating, aggravated after weight lifting, worse before defecation decreasing after defecation, pain worry both night and day; periodic burning pain in epigastria, arising after a meal in 15-20 min, burning tongue and palate after eating after 15-20 minutes, occasionally bitter taste in the mouth, heartburn after eating; bloating and rumbling in the stomach; diarrhea to 2 times a day, chair , brown, not plentiful, with greasy luster, without any admixture of mucus and blood. Notes intolerance to dairy and sour-milk products. Appetite saved. Weight stable.

History of present illness: considers himself to be ill with 2008, when for the first time appeared aching pain in left hypochondrium, burning the sky and language, appeared chair up to 2 times day. He began to notice the intolerance to dairy products. Outpatient at endoscopy revealed signs of failure of the cardia, erosive gastritis. When ultrasound examination of the abdominal cavity - a cholesterosis of a gall bladder. Took rabeprazole within 4 weeks, with a positive effect. Passed hospital treatment. At endoscopy - signs of chronic gastritis, failure of the cardia, urease test is negative. When ultrasound examination of the abdominal cavity - hepatic steatosis, deformity of the gallbladder, pancreas. During the colonoscopy - dyskinesia of large intestine passages as to hypermotor type. Treatment: omeprazole, famotidine, , furazolidone powder with white clay with a weak positive effect. Outpatient x-ray study of the stomach and small intestine revealed cicatricial deformity of the duodenum. Deterioration since February of this year, when heartburn and burning the sky and language intensified, reappeared chair up to 2 times day. Consulted, ds: GERD in the stage of reflux esophagitis. Rivers but: the reception of Epicurus on 1 t x 2 R./D. with a weak positive effect.

Objectively when you receive: a satisfactory condition, HELL 115/78 mm RT. senior HR 70 min. BH 18 minutes muffled heart sounds, rhythm right. In light of wheezing no, vesicular breath. Tongue wet, white furred. Abdomen soft, not swollen, moderately painful in the epigastrium and region. The chair was 1 per day, designed, not plentiful, without pathological admixtures. The expansion of the umbilical ring.

The results of the survey:

ECG: normal position of the EOS. HR 61. Rhythm sinus correct.

Sigmoidoscopy: on external inspection finger study - 12 h - skin pinch - guard-bump», and rendered Muco-cutaneous defect anus, moderately painful on palpation. Determined rectocele 1-2 tbsp.; internal hemorrhoids are moderately pronounced in typical places, not tense, hypertrophied anal papillae. Sphincter tone saved. Tube introduced by 20 cm due to the presence of feces in the lumen of the usual colors. On visible areas of the slimy pink, smooth, shiny, vascular figure traced. At a distance of 15 cm from the anus to wall visualized polyp diameter up to 0.4 cm on a broad basis with unchanged tip - biopsy. Another pathology was revealed. Conclusion: Chronic anterior anal fissure in the phase of exacerbation. Rectocele 1-2 . hemorrhoids, remission. The gut polypus. Biopsy: tubular adenoma of the colon.

EMA intestine: hypermotor dyskinesia of the stomach choledochus and descending aorta colon. Neurologist: whiplash .

EGD: Esophagus pass. Esophageal mucosa is pale pink, cardia not closed, reflux. Stomach: stomach cavity moderate amount of mucous content. The mucosa of the stomach pale pink, hyperemic in the form of bands in the antrum. Folds smooth and elastic. Peristalsis is traced in all departments. The angle of the stomach is not modified. The porter closed, we pass. Onion duodenum medium size, moderate deformed. The mucosa of the duodenal pale pink, swollen. The folds of medium size, elastic. Skinny gut on the tops of the folds. Urease test is negative. test weakly positive. Conclusion: chronic gastritis, failure of the cardia, reasonable deformation of the duodenal bulb. Biopsy: chronic weak and duodenitis.

Ultrasound SSB: Liver: visualizes adequately; not acting under the edge of a costal arch. Edge rounded, smooth, outline a clear, capsule is not thickened. The size of the liver are not enlarged (HDP the right lobe of the 152 mm, the thickness of the left lobe of 67 mm). Structure is homogeneous. Total echogenicity parenchyma increased, expressed fat component. Diameter of the portal vein 12.0 mm, diameter NIP 22,0 mm; clearance homogeneous. Vascular figure saved, is not deformed. Gall bladder: the correct form. Dimensions are not enlarged: 62 x 29 x 34 mm, volume 33 ml of the bladder Wall hardened and thickened (up to 3.3 mm), homogeneous structure. In the cavity of a bubble is defined sediment (suspended), concrements no. ducts are not extended, the lumen of the homogeneous. The common bile duct is not extended (4,7 mm), the walls are sealed, clearance homogeneous. The pancreas is rendered satisfactory, contour fuzzy, uneven surface. Dimensions: 33,0 x 19,2 x 22.7 mm frame impure, unevenly sealed. Total echo is increased. Pancreatic duct is not expanded. Spleen is rendered adequately, contour fuzzy, surface smooth, sealed capsule. Dimensions: 114 x 54 mm R 40 cm 2 . (N47 cm 2 ). The structure of the inhomogeneous (on the average a segment is defined collection of calcifications, average diameter up to 3.4 mm), shared echo is average. Vienna diameter of 7.8 mm, clearance homogeneous. Free fluid in the abdominal cavity no.

Ultrasound of liver steatosis, a cholesterosis of a gall bladder, diffuse changes of the pancreas, calcification of the parenchyma of the spleen. Colonoscopy: the device held in the dome of the cecum. Б flap , focuses dome. In the right departments colon moderate amount of the liquid contents. When ulcer marked pain syndrome. The mucosa of the colon at the inspected sites pink, smooth, shining. Vascular drawing antialiased. The folds of mucous average, elastic. The lumen is not deformed. The tone of the ulcer saved. Conclusion: organic pathology was revealed.

Consultation of endocrinologist: ds: an Increase in thyroid 1 tbsp., . Recommended outpatient thyroid ultrasound, blood test (TSH and free T4.). A surgeon ds: tubular adenoma of the colon. Recommended surgical removal of the adenoma. Breath hydrogen test with lactulose (30 ml): a bacterial overgrowth (62 ppm). EGD (control): a chronic gastritis, a failure of the cardia, reasonable deformation of the duodenal bulb. test is negative. Breath hydrogen test with lactulose (30 ml): bacterial overgrowth is not revealed (12 ppm). Laboratory data:

The General analysis of a blood:

Indicator

Norm

Indicator

Norm

Hemoglobin

13,2 16

P/nuclear

2 1-6

Erythrocytes

4,58 3,9-5,3

The segment.

54 47-72

Hematocrit

40,4 39-50

Eosinophiles

2 0-5

Leukocytes

3,9 4-9

Lymphocytes

36 19-37

Platelets

232 150-400

Monocytes

6 3-11

Erythrocyte sedimentation rate

6 3-15

Biochemical analysis of blood

Indicator

09.03.11 Norm

About. protein

68,3 66-87

Total bilirubin

7,8 3,4-21 Glucose 6,06 4,1-5,9

Cholesterol

5,94 1,4-5,2 Urea 5,56

of 1.7 to 8.3

MHO 0,95 0,9-1,2

Prothrombin

100 70-130

Indicator

Result Date HIV

negativity.

14.03.11 RW

negativity.

14.03.11

Glucose tolerance test - glucose level to load the 5.45 mmol/l after load - 6,58 mmol/L. Markers of hepatitis b and C is not found.

Clinical analysis of urine - transparent, protein neg., beats./weight 1032, leukocytes neg., erythrocytes neg., ketones, glucose - no. Fecal occult blood - negativity. Treatment: diet, daily - Mezym Forte 1 table x 3 times, Bifiform 1 tab. 2 times and no-Spa - 1 table. 3 times a course of treatment for 14 days.

reduction EMA duodenum. Hypermotor dyskinesia of the descending aorta colon.

Against the background of therapy the patient notes improvement in their condition: decrease heartburn, disappearance of pain in the region, normalization of stool up to 1 R/d, issued without admixture of mucus blood.

The treatment of 96 patients with secondary lactase deficiency. The research confirmed the achievement of the objective of the invention is increasing the effectiveness of treatment of secondary lactase deficiency.

The method of treatment of secondary lactase deficiency, including diet and drug therapy is characterized in that in the capacity of medicinal preparations is used as a daily dose Bifiform 1 tab. 2-3 times and no-Spa - table 1-2. 3 times a course of treatment for 14 days.